Changes in the brain can occur 10-20 years before Alzheimer's disease symptoms appear. Care Access's Abigail Baldwin told us their new research study targets this "silent stage" of Alzheimer's. Recent advances in research allow can now detect people in the early stages of Alzheimer's with an investigational blood test. Early intervention during this stage may prevent or prolong the time until symptoms start. The Trailblazer-ALZ 3 study is a new research study of the drug donanemab, sponsored by Eli Lilly and Company, which may help researchers to potentially prevent or slow down the symptoms of Alzheimer's disease. They are recruiting 33,000 participants ages 55-80 for the study who do not have symptoms of Alzheimer's disease. Participants will receive a series of shots of either donanemab or a placebo and researchers will measure cognitive function over time and track their immune response and the levels of the study drug in the participants' blood. Alzheimer's disease affects one in nine people age 65 and older, and one in three of those with Alzheimer's or another dementia will die.